(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 13.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Adaptive Biotechnologies's revenue in 2026 is $308,081,000.On average, 11 Wall Street analysts forecast ADPT's revenue for 2026 to be $47,767,035,511, with the lowest ADPT revenue forecast at $45,451,299,843, and the highest ADPT revenue forecast at $49,769,963,328. On average, 11 Wall Street analysts forecast ADPT's revenue for 2027 to be $58,467,936,717, with the lowest ADPT revenue forecast at $53,959,354,180, and the highest ADPT revenue forecast at $62,213,651,128.
In 2028, ADPT is forecast to generate $71,639,381,557 in revenue, with the lowest revenue forecast at $63,771,306,546 and the highest revenue forecast at $78,125,356,576.